

PUBBLICAZIONI 2024

Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators' Group; ELATIVE Study Investigators' Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. *N Engl J Med*. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. PMID: 37962077 Clinical Trial.

Barda B, Di Mari B, Soldini E, Di Bartolomeo C, Bissig M, Baserga A, Robatto A, Magenta L, Forlenza R and Cerny, A. Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial. *Sci. Pharm.* 2024, 92(4), 56; <https://doi.org/10.3390/scipharm92040056>

Kälin T, Passarin K, Filipowicz-Sinnreich M, Semela D, Seifert T, Sallusto F, Vergani D, Cerny A, Mieli-Vergani G, Terziroli Beretta-Piccoli B; Swiss Autoimmune Hepatitis Cohort Study; Swiss Primary Biliary Cholangitis Cohort Study; Swiss Primary Sclerosing Cholangitis Study. SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases. *J Autoimmun.* 2024 Dec;149:103325. doi: 10.1016/j.jaut.2024.103325. Epub 2024 Oct 15. PMID: 39413503

Consolascio D, Bronz G, Lardelli PF, Milani GP, Lava SAG, Terziroli Beretta Piccoli B, Bianchetti MG, Bergmann MM, Rizzi M. Hoigné's syndrome, an uncommon mimicker of anaphylaxis: Systematic literature review. *J Autoimmun.* 2024 Jan 8;143:103164. doi: 10.1016/j.jaut.2023.103164. [Impact factor 12.8; Maximum ranking 0.916]

Razavi H, Blach S, Bregenzer A, Bruggmann P, Cerny A, Maeschli B, Müllhaupt B, Negro F, Scheidegger C, Semela D. Response to "Reply to 'Assessing the hepatitis C epidemiology in Switzerland: It's not that trivial'". *J Viral Hepat.* 2024 Jun;31(6):357-359. doi: 10.1111/jvh.13904. Epub 2023 Dec 8. PMID: 38069467 No abstract available.

Montano-Loza AJ, Lytvyak E, Hirschfield G, Hansen BE, Ebadi M, Berney T, Toso C, Magini G, Villamil A, Nevens F, Van den Ende N, Pares A, Ruiz P, Terrabuio D, Trivedi PJ, Abbas N, Donato MF, Yu L, Landis C, Dumortier J, Dyson JK, van der Meer AJ, de Veer R, Pedersen M, Mayo M, Manns MP, Taubert R, Kirchner T, Belli LS, Mazzarelli C, Stirnimann G, Floreani A, Cazzagon N, Russo FP, Burra P, Zigmound U, Hourri I, Carbone M, Mulinacci G, Fagioli S, Pratt DS, Bonder A, Schiano TD, Haydel B, Lohse A, Schramm C, Rüther D, Casu S, Verhelst X, Beretta-Piccoli BT, Robles M, Mason AL, Corpechot C; Global PBC Study Group.

Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation. *J Hepatol.* 2024 Oct;81(4):679-689. doi: 10.1016/j.jhep.2024.05.010. Epub 2024 May 29. PMID: 38821360. [Impact factor 25.7; Maximum ranking 0.962]

Efe C, Uzun S, Matter MS, Terziroli Beretta-Piccoli B. Autoimmune-Like Hepatitis Related to SARS-CoV-2 Vaccination: Towards a Clearer Definition. *Liver Int.* 2025 Jan;45(1). doi: 10.1111/liv.16209. PMID: 39673711.

Kramer M, Mele F, Jovic S, Fernandez BM, Jarrossay D, Siong Low J, Sokollik C, Filipowicz Sinnreich M, Ferrari-Lacraz S, Mieli-Vergani G, Vergani D, Lanzavecchia A, Cassotta A, Terziroli Beretta-Piccoli B, Sallusto F. Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis. *Journal of Clinical investigation* 2025, in press

Moschouri E, Salemme G, Baserga A, Cerny A, Deibel A, Müllhaupt B, Meier MA, Bernsmeier C, Ongaro M, Negro F, Grosjean M, Clerc O, Künzler-Heule P, Semela D, Hobi G, Stickel F, Mathieu A, Mdawar-Bailly E, Faouzi M, Moradpour D, Fraga M. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis. *Swiss Med Wkly.* 2024 Jun 24;154(6):3698. doi: 10.57187/s.3698. PMID: 38980176

Efe C, Lytvyak E, Eşkazan T, Liberal R, Androutsakos T, Turan Gökçe D, Terziroli Beretta-Piccoli B, Janik M, Bernsmeier C, Arvaniti P, Milkiewicz P, Batibay E, Yüksekayla O, Ergenç I, Arikian Ç, Stättermayer AF, Barutçu S, Cengiz M, Gül Ö, Heurgue A, Heneghan MA, Verma S, Purnak T, Törüner M, Akdoğan Kayhan M, Hatemi I, Zachou K, Macedo G, Drenth JPH, Björnsson E, Montano-Loza AJ, Wahlin S, Higuera-de la Tijera F. Efficacy and safety of infliximab in patients with autoimmune hepatitis. *Hepatology.* 2024 Sep 6. doi: 10.1097/HEP.0000000000001089. Epub ahead of print. PMID: 39250458.

Bernasconi GF, Milani GP, De Felice ELT, Laurence C, Faré PB, Terziroli Beretta-Piccoli B, Bianchetti MG, Lava SAG. Acute aseptic meningitis temporally associated with trimethoprim and sulfamethoxazole: Systematic review. *Br J Clin Pharmacol.* 2025 Jan;91(1):236-243. doi: 10.1111/bcp.16346. Epub 2024 Nov 14. PMID: 39540422.

Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune

and cholestatic liver disease. *Front Immunol.* 2024 Jan 24;15:1369747. doi: 10.3389/fimmu.2024.1369747. PMID: 38268921; PMCID: PMC10805832.

Blach S, Bregenzer A, Bruggmann P, Cerny A, Maeschli B, Müllhaupt B, Negro F, Razavi H, Scheidegger C, Semela D. Assessing the hepatitis C epidemiology in Switzerland: It's not that trivial. *J Viral Hepat.* 2024 Jan;31(1):51-52. doi: 10.1111/jvh.13879. Epub 2023 Aug 8. PMID: 37551747.

Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Gasbarrini A, Dumortier J, Riveiro Barciela M, Gevers TG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Rösner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode S, Schulze K. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease. *Front Immunol.* 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078, PMID: 38268921

Weltzsch JP, Bartel CF, Waldmann M, Renné T, Schulze S, Terziroli Beretta-Piccoli B, Papp M, Oo Ye, Ronca V, Sebode M, Lohse AW, Schramm C, Hartl J. Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol. *Hepatol* 2024, in press. [Impact factor 13.5; Maximum ranking 0.930]

Abegg VF, Panajatovic MV, Mancuso RV, Allard JA, Duthaler U, Odermatt A, Krähenbühl S, Bouitbir J. Mechanisms of hepatocellular toxicity associated with the components of St. John's Wort extract hypericin and hyperforin in HepG2 and HepaRG cells., *Toxicol Lett.* 2024 Jan 14;393:1-13

Ozbey AC, Keemink J, Wagner B, Pugliano A, Krähenbühl S, Annaert P, Fowler S, Parrott N, Umehara K. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam. *Drug Metab Dispos* 2024;52:614-625

Duthaler U, Chapuisat F, Hanimann R, Krähenbühl S. Effect of protein binding on the pharmacokinetics of the six substrates in the Basel phenotyping cocktail in healthy subjects and patients with liver cirrhosis. *Eur J Pharm Sci.* 2024;202:106885